Table 4. Cox regression models of variables associated with stavudine associated side effects.
| Variable | Peripheral Neuropathy | Lipodystrophy | Any toxicity¶ | |||
| HR (95%-CI) | aHR (95%-CI) | HR (95%-CI) | aHR (95%-CI) | HR (95%-CI) | aHR (95%-CI) | |
| Male gender | 1.26 (0.64–2.48) | 1.67 (0.59–4.72) | 0.73 (0.23–1.41) | 0.73 (0.23–2.40) | 1.05 (0.61–1.81) | 1.08 (0.48–2.42) |
| Age (years) | 1.04 (1.02–1.08) | 1.04 (1.00–1.08) | 1.06 (1.03–1.11) | 1.08 (1.04–1.13) | 1.05 (1.02–1.08) | 1.05 (1.02–1.08) |
| BMI (kg/m2) | 1.05 (0.99–1.14) | 1.07 (0.97–1.18) | 0.98 (0.87–1.10) | 0.97 (0.84–1.12) | 1.07 (1.00–1.15) | 1.08 (0.99–1.17) |
| WHO stage * | 1.36 (0.70–2.64) | 1.68 (0.82–3.44) | 0.52 (0.22–1.26) | 0.37 (0.14–0.98) | 0.95 (0.55–1.65) | 0.96 (0.53–1.74) |
| Alcohol use | 0.74 (0.10–5.74) | 1.00 (0.13–7.85) | 0.46 (0.06–3.31) | 0.63 (0.08–4.79) | ||
| TB diagnosis † | 0.65 (0.27–1.58) | 0.61 (0.24–1.58) | 0.92 (0.48–1.75) | 1.15 (0.56–2.34) | ||
| eCC (mL/min) | 1.00 (0.99–1.02) | 0.99 (0.96–1.01) | 0.98 (0.96–1.00) | 0.99 (0.96–1.02) | 1.00 (0.99–1.01) | 0.99 (0.96–1.01) |
¶
One or more of peripheral neuropathy, lipodystrophy, pancreatitis, high lactate syndrome, diabetes mellitus.
HR, hazard ratio; aHR, adjusted hazard ratio; CI, confidence interval, BMI, body mass index; WHO, world health organization; TB, tuberculosis;
eCC, estimate creatinine clearance.
*
WHO stage refers to being in WHO clinic stage 3 or 4 vs. being in stage 1 or 2 at the start of ART. Significant associations are indicated in bold font.
†
TB diagnosis refers to previous and current diagnosis.